37 results on '"Pawarode, Attaphol"'
Search Results
2. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
3. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis
4. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
5. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation
6. Pneumocystis Jirovecii Infection in Autologous Hematopoietic Stem Cell Transplant Recipients
7. Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)
8. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
9. Survival following allogeneic transplant in patients with myelofibrosis
10. Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot Study
11. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
12. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
13. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
14. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease
15. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
16. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
17. Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment
18. An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation
19. Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
20. Prognostic Value of TGFβ at Diagnosis of Chronic GvHD
21. Pneumocystis Jirovecii Pneumonia In Recipients Of Autologous Hematopoietic Stem Cell Transplantation: A 10-Year Cohort Study
22. Application Of BOS 0-Potential Criteria As a Predictor For Bronchiolitis Obliterans Syndrome In Allogeneic Stem Cell Transplant Patients
23. Unrelated Donor Transplants for Older AML Patients Using a Low Dose TBI Containing Regimen Are As Efficacious As Related Donor Transplants, and Exhibit Favorable Outcomes for Intermediate Risk Disease.
24. Targeting Histone Deacetylases As a New Strategy for Graft Versus Host Disease Prevention
25. An Algorithm Combining Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Future Graft-Versus-Host Disease Following Related Donor Hematopoietic Cell Transplantation
26. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies
27. Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease
28. Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML
29. Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.
30. Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.
31. Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity Transplants.
32. Long-Term Outcome of Cyclosporin A Therapy for T-Cell Large Granular Lymphocyte Leukemia.
33. The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.
34. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.
35. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
36. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.
37. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.